[A new antihypertensive agent used in a clinical setting]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertension is a significant global health concern requiring effective and safe pharmacological interventions.
• Guanfacine and clonidine are known antihypertensive agents with distinct pharmacological profiles.

Purpose of the Study:

• To compare the antihypertensive efficacy and safety of guanfacine versus clonidine.
• To evaluate side effect profiles in patients with essential and renal hypertension.

Main Methods:

• A double-blind, cross-over, multicenter study involving 54 patients with hypertension (WHO I-III).
• Patients received either guanfacine or clonidine for five weeks, followed by a two-week placebo wash-out period.
• Blood pressure and heart rate were monitored, and side effects were recorded.

Main Results:

• Both guanfacine (3.3 mg/day) and clonidine (0.5 mg/day) significantly reduced blood pressure within two weeks.
• Guanfacine demonstrated a slightly smaller reduction in blood pressure in the upright position compared to clonidine.
• Side effects, including dry mouth and tiredness, were more frequent and pronounced with clonidine (p ≤ 0.08).

Conclusions:

• Guanfacine is a well-tolerated antihypertensive drug with a favorable safety profile.
• Guanfacine offers a viable alternative to clonidine for managing hypertension, particularly concerning side effect burden.